The majority of Jehovah's Witnesses refuse blood product transfusion, even when it can be lifesaving. Treatment with recombinant human erythropoietin (RHuEPO) is a valuable adjunct in Jehovah's Witness patients undergoing surgery. A number of additional strategies, including acute normovolaemic haemodilution, intra-operative blood salvage and reinfusion, iron and folate supplementation are also utilized to avoid blood transfusion. Critically ill patients have blunted erythropoietin production and decreased endogenous iron availability. This case report reviews the treatment of anaemia in critically ill Jehovah's Witness patients after surgery and discusses the potential need for higher RHuEPO dosing strategies and longer duration of therapy.
Recombinant human erythropoietin (RHuEPO) has become a viable alternative to blood transfusion in patients with anaemia or other disorders precluding donation, patients with limited time to surgery and individuals who, due to religious beliefs, are unwilling to participate in an autologous blood donation program or blood transfusion. The religious beliefs of Jehovah's Witnesses prohibiting the acceptance of blood or blood product transfusion are well recognized; hence treatment options for these patients are limited. This is particularly true for loss.
CASE HISTORY
A 72-year-old female Jehovah's Witness presented to the oral and maxillofacial surgeons complaining of a three-month history of a lump on the palate with associated dysphagia, otalgia, changes in vision and headaches. Examination revealed a palpable swelling on the right side of the soft palate and lateral pharyngeal wall with no associated cervical lymphadenopathy. CT and MRI scans demonstrated a palatal mass with base of tongue involvement and extension into and vidian canal leading to the cranial base. Biopsy Preoperatively, the patient declined any therapy involving blood or blood-related products including coagulation factors and autologous transfusion. A wide local excision involving the soft palate, right posterior maxilla and right pterygoid plates and performed with 500 ml estimated blood loss.
Admitted to the intensive care unit (ICU) in a stable haemodynamic condition, her haematocrit (Hct) fell from 41.7% preoperatively to 25.1% in the immediate postoperative period. Recombinant human erythropoietin (RHuEPO, 20,000 units maintenance of optimal perfusion, substantiated by day 2 (Table 1) . A high-dose regimen of RHuEPO 40,000 units per day with intravenous iron sucrose 100 mg per day was initiated. (Table 2) .
Additional strategies to prevent iatrogenic blood loss in the ICU included ordering only essential laboratory tests and using microsample analysers for all diagnostic laboratory testing. The RHuEPO dose was subsequently decreased to 20,000 units per week when the Hct increased to 22.1%. Furthermore, ferrous sulphate 300 mg p.o., t.i.d. and ascorbic acid 500 mg p.o., b.i.d. were administered until discharge on postoperative day 22 ( Figure 1 ). been documented in anaemic, non-traumatized, critically ill patients [5] [6] [7] . Furthermore, inadequate endogenous erythropoietin response to low haemoglobin was documented in multiply traumatized patients .
The pathogenesis of the inadequate endogenous erythropoietin response in critically ill patients is multifactorial, including down-regulation of the direct inhibitory effect on bone marrow red blood cytokines (interleukin-1 and tumor necrosis factor-) and altered iron metabolism (low transferrin, sepsis.
The mechanisms underlying the anaemia of activation of T cells (CD3+) and monocytes. These cells induce immune effector mechanisms, thereby producing cytokines such as interferon (from T cells) and tumor necrosis factor (TNF-), interleukin (IL)-1, IL-6, and IL-10 (from monocytes or macrophages). Interleukin-6 and lipopolysaccharide stimulate hepatic expression of the acute-phase protein hepcidin, which inhibits duodenal absorption of iron. Interferon-gamma and lipopolysaccharide also increase the expression of divalent metal transporter 1 on macrophages and stimulate the IL-10 upregulates transferrin receptor expression and increases transferrin-receptor-mediated uptake of transferrin bound iron into monocytes. Additionally, activated macrophages phagocytose and degrade senescent erythrocytes for iron recycling, a TNF induced process via damaging of erythrocyte membranes and stimulation of phagocytosis. Interferon-gamma and lipopolysaccharide downregulate the macrophage iron transporter ferroportin 1 expression, thus inhibiting iron export from macrophages, a hepcidin-mediated process. Simultaneously, TNF , IL-1, IL-6 and IL-10 induce ferritin expression and stimulate macrophage storage and retention of iron.
In summary, these mechanisms initiate a decreased iron concentration in the circulation, thereby limiting iron availability for erythroid cells. TNF and interferon-gamma inhibit renal erythropoietin production. TNF , interferon-gamma, and IL-1 directly inhibit differentiation and proliferation of erythroid progenitor cells. Additionally, limited iron availability and decreased biologic activity of erythropoietin cause inhibition of erythropoiesis and the development of anaemia. 
DISCUSSION
Erythropoiesis is regulated by the glycopeptide erythropoietin. Binding to BFU (burst-forming unit) and CFU (colony-forming unit) receptors of the premature erythrocyte, erythropoietin effect on the survival and maturation of precursor cells 1 . Tissue hypoxaemia represents the maximum stimulus for increased endogenous erythropoietin release 2 .
"Anaemia of critical illness" mimics the anaemia endogenous erythropoietin production 3, 4 
. Inadequate endogenous erythropoietin concentrations have
RHuEPO enhances endogenous erythropoiesis, and is accepted by most Jehovah's Witnesses. Optimal dose and dosing regimen of RHuEPO remains unclear, especially when treating critically ill patients with life-threatening acute blood loss and those with severe acute anaemia who refuse transfusion 10 .
The role of RHuEPO has been investigated in a simulated peri-surgical setting 11 . With differing RHuEPO dosing regimens, the study showed a consistent rise in absolute reticulocyte count and haematocrit within seven days with a peak at 14 days. In a study of 201 patients undergoing hip arthroplasty, the peri-operative use of RHuEPO caused an increased reticulocyte count by day 4 after the initial dose. The greatest increase in reticulocyte count occurred in patients who received the high dose (40,000 units weekly) 12 .
A prospective, randomized, placebo-controlled trial documented that RHuEPO (300U/kg daily for 5 days, then every other day dosing) was associated with increased erythrocyte production and decreased blood transfusion requirements in the critically ill 13 . A subsequent prospective randomized study administration of 40,000 units of RHuEPO also reduced allogeneic blood transfusion and increased haemoglobin concentration 14 .
Georgopoulos et al 15 , in a prospective randomized trial in critically ill patients, compared RHuEPO at 40,000 units per week (group A) vs 40,000 units three time a week (group B) for a maximal three-week duration, compared to a control group that received mean haematocrit increase was documented with the higher RHuEPO dosing (group B) schedule. Thus, we chose empirically a high dose of 600 IU/kg -1 everyday for a week in this patient with severe acute anaemia. erythropoietin concentrations in critically ill patients 16 . Patients were randomized to RHuEPO (300 IU/kg every other day) with IV iron (20 mg daily) and folate vs. folate only or IV iron and folate. Reticulocyte count only in the RHuEPO group.
Jehovah's Witnesses have challenged the traditional approach to transfusion therapy. While many clinicians would consider blood transfusions for a patient with that acute morbidity and mortality generally does not occur in this patient population until the haemoglobin drops below 5-6 g/dl. Survival has been reported in a few cases of Jehovah's Witnesses undergoing operative procedures with haemoglobin ranging from 2.2-3.0 g/dl .
In this case, severe anaemia occurred postoperatively related to surgical blood loss and haemodilution. The increase in haematocrit was attributable to treatment of anaemia with RHuEPO and reduced phlebotomy. Alternative blood management strategies that were considered in this patient included the use of pre-operative RHuEPO approximately three to four weeks before the anticipated surgery. However, a higher than normal haematocrit (42%) in the preoperative period precluded its utility. Preoperative anaemia would have warranted the use of RHuEPO with iron, folate and Vitamin C and surgery would have been delayed until haematocrit was optimized. Other feasible strategies included acute normovolaemic haemodilution (ANH). Intra-operative blood salvage and reinfusion in oncologic surgery is relatively contraindicated because of the risk of tumor cell dissemination. However, intra-operative blood salvage with blood irradiation has shown promise in the presence of malignant disease 20 . Meticulous surgical haemostasis is paramount.
The most common adverse event related to well to simple supportive treatment. Hypertension, thrombocytosis and thrombosis, allergic or anaphylactoid reactions, seizure and hyperkalaemia have also been reported 21 . They are associated with a rapid rise in haematocrit during RHuEPO therapy and clinical vigilance will minimize these adverse reactions. A rare complication, pure red cell aplasia, has been reported due to the development of antibodies to Eprex, an epoetin alpha product available outside the U.S. 22 . The high-dosing strategy of RHuEPO for the treatment of severe anaemia in this critically ill patient has demonstrated its safety, utility and feasibility. Because of enhanced erythropoiesis with RHuEPO, iron, folate and ascorbic acid supplementation should be administered routinely. Adequate nutrition is also important in sustaining erythropoiesis. The use of high-dose daily RHuEPO and iron in managing Jehovah's Witnesses with severe anaemia, in addition to existing strategies of blood conservation, should be considered by clinicians caring for these challenging patients. Further research is warranted regarding optimal dosing and duration of RHuEPO in critically ill patients with severe anaemia related to reduced endogenous erythropoietin production and decreased iron availability.
